Coherus Biosciences Inc (NASDAQ:CHRS) Given Average Rating of “Buy” by Analysts

Coherus Biosciences Inc (NASDAQ:CHRS) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $30.29.

CHRS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Coherus Biosciences in a report on Monday, November 25th. Credit Suisse Group reiterated a “buy” rating and issued a $36.00 price target on shares of Coherus Biosciences in a report on Friday, November 8th. ValuEngine cut shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 10th. TheStreet upgraded shares of Coherus Biosciences from a “d-” rating to a “c-” rating in a report on Thursday, November 7th. Finally, Mizuho initiated coverage on shares of Coherus Biosciences in a report on Wednesday, November 27th. They set a “buy” rating and a $43.00 target price on the stock.

NASDAQ:CHRS traded up $0.05 during trading hours on Thursday, hitting $19.86. The company had a trading volume of 21,541 shares, compared to its average volume of 914,471. The company has a market capitalization of $1.39 billion, a PE ratio of -6.18 and a beta of 2.89. The stock has a 50-day moving average price of $18.16 and a 200 day moving average price of $19.25. Coherus Biosciences has a 52 week low of $10.83 and a 52 week high of $23.91. The company has a debt-to-equity ratio of 3.37, a current ratio of 3.34 and a quick ratio of 3.25.

Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.27. The company had revenue of $111.68 million during the quarter, compared to the consensus estimate of $93.58 million. Analysts anticipate that Coherus Biosciences will post 1.36 EPS for the current fiscal year.

In other news, CFO Jean-Frederic Viret sold 1,388 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $19.02, for a total transaction of $26,399.76. Following the sale, the chief financial officer now owns 6,385 shares in the company, valued at approximately $121,442.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Vincent R. Anicetti sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $18.69, for a total transaction of $46,725.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 837,659 shares of company stock worth $15,091,914. Company insiders own 18.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Cutler Group LP bought a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $32,000. Tower Research Capital LLC TRC bought a new stake in shares of Coherus Biosciences during the 3rd quarter valued at $52,000. Public Employees Retirement System of Ohio bought a new stake in shares of Coherus Biosciences during the 2nd quarter valued at $75,000. Hoey Investments Inc. bought a new stake in shares of Coherus Biosciences during the 4th quarter valued at $66,000. Finally, Bank of Montreal Can bought a new position in Coherus Biosciences in the 2nd quarter worth about $114,000. Hedge funds and other institutional investors own 98.62% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Read More: Is a Roth IRA right for you?

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit